Online inquiry

IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11094MR)

This product GTTS-WQ11094MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CSF1 gene. The antibody can be applied in Pigmented villonodular synovitis (PVNS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000757.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1435
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11094MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8122MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ10962MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ4008MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ2375MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ14418MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ1639MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ12692MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ13369MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PR-1498487
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW